mesothelin-specific CAR T cells

Mesothelin-specific CAR T cells are genetically engineered T cells that express a chimeric antigen receptor (CAR) targeting **mesothelin**, a cell surface glycoprotein highly expressed in multiple solid tumors including mesothelioma, pancreatic cancer, ovarian cancer, lung cancer, and triple-negative breast cancer. The CAR construct typically contains an anti-mesothelin binding domain (commonly a single-chain variable fragment—scFv), and intracellular signaling domains (e.g., CD3-zeta and a costimulatory domain like 4-1BB or CD28) to activate T-cell cytotoxicity upon mesothelin engagement. Unlike conventional T cells, these engineered cells recognize mesothelin-expressing cancer cells directly, independent of MHC, and mediate tumor cell lysis through T-cell activation. Various generation strategies exist, including transient CAR expression via mRNA electroporation for safety and stably transduced CARs for sustained activity. Mesothelin-specific CAR T-cell therapies are under clinical investigation primarily for advanced or refractory cancers with high mesothelin expression[1][2][4][5].

Other names

mesothelin-targeted CAR T cellsanti-mesothelin CAR T cells